Lineage Cell Therapeutics Inc (LCTX)
AMEXHealth CareBiotechnologySnapshot 2026-09-04
$1.08-1.82%
Close 2026-09-04 · 1-day change
AMEXHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · LCTX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 13.1 | 14.6 | 9.5 | 8.9 | 14.7 | 4.3 | 1.8 | 3.5 | 5.0 | 3.5 | 5.9 | 7.0 | 5.2 | 4.4 | 3.9 | 4.4 |
| Total Revenues | 13.1 | 14.6 | 9.5 | 8.9 | 14.7 | 4.3 | 1.8 | — | — | 3.5 | 5.9 | 7.0 | 5.2 | 4.4 | 3.9 | 4.4 |
| Cost of Revenues | — | — | 0.3 | 0.7 | 0.7 | 1.4 | 0.4 | 0.4 | 0.3 | 0.2 | 0.4 | 1.1 | 0.8 | 0.8 | 0.4 | — |
| Gross Profit | — | — | — | 8.3 | 14.0 | 2.9 | 1.4 | 3.1 | 4.7 | 3.3 | 5.6 | 5.9 | 4.4 | 3.6 | 3.5 | — |
| Operating Expenses & Income | ||||||||||||||||
| R&D Expenses | 20.5 | 17.7 | 12.5 | 15.7 | 14.0 | 33.9 | 12.3 | 17.9 | 21.0 | 24.0 | 36.1 | 42.6 | 37.5 | 26.6 | 18.1 | 13.7 |
| Other Operating Expenses, Total | — | — | — | — | — | — | 0.0 | — | — | — | — | — | — | — | — | — |
| Operating Income | (26.9) | (36.6) | (21.5) | (24.7) | (22.5) | (49.2) | (26.4) | (38.9) | (41.8) | (38.9) | (59.0) | (65.8) | (50.7) | (56.0) | (25.0) | (18.7) |
| Earnings from Continuing Operations | ||||||||||||||||
| Other Non-Operating Income / Expenses | (10.5) | (32.0) | 2.9 | 1.5 | (3.3) | 5.9 | 4.5 | 19.6 | (5.3) | 15.6 | 77.6 | 3.2 | (0.5) | (0.2) | (0.3) | 0.2 |
| Asset Writedown | — | — | — | 0.0 | 0.0 | — | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | — | (68.6) | (18.6) | (23.3) | (25.8) | (43.3) | (21.9) | (19.2) | (47.1) | (23.3) | 18.6 | (62.7) | (51.2) | (56.2) | — | — |
| Income Tax Expense | — | (5.3) | — | (1.8) | 0.5 | — | (1.2) | (7.4) | 0.3 | — | — | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Minority Interest | 0.2 | 0.2 | 0.0 | 0.0 | (0.1) | (0.3) | (0.0) | (0.1) | (0.8) | (3.3) | (15.0) | (11.1) | (7.4) | (9.0) | (3.9) | (1.9) |
| Net Income | (32.3) | (63.5) | (18.6) | (21.5) | (26.3) | (43.0) | (20.6) | (11.7) | (46.0) | (20.0) | 33.6 | (47.0) | (36.4) | (43.9) | (21.4) | (16.5) |
| Per Share | ||||||||||||||||
| Basic EPS | (0.13) | (0.28) | (0.09) | (0.12) | (0.15) | (0.26) | — | — | — | (0.17) | 0.35 | — | — | — | — | — |
| Diluted EPS | (0.12) | (0.28) | (0.09) | (0.12) | (0.15) | — | — | — | — | (0.17) | 0.34 | — | — | — | — | — |
| Revenue per Share | 0.05 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 249.5 | 230.1 | 200.2 | 172.7 | 169.8 | 164.5 | — | — | — | 114.5 | 97.3 | — | — | — | — | — |
| Diluted Weighted Avg Shares | 261.5 | 230.1 | 200.2 | 172.7 | 169.8 | — | — | — | — | 114.5 | 99.6 | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (35.9) | (20.9) | (24.2) | (21.9) | (48.5) | (25.6) | (37.9) | (40.7) | (38.0) | (57.8) | — | — | — | — | — |
| EBIT | (26.9) | (36.6) | (21.5) | (24.7) | (22.5) | (49.2) | (26.4) | (38.9) | (41.8) | (38.9) | (59.0) | (65.8) | (50.7) | (56.0) | (25.0) | (18.7) |
| Effective Tax Rate | — | — | — | 7.7% | -2.1% | — | 5.7% | 38.5% | -0.7% | — | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.